Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. (Q38164652)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24259600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24259600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

main subject

tuberculosis

0 references

multiple drug resistance

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24259600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Elias B Chahine

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24259600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Lamis R Karaoui

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24259600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

language of work or name

English

0 references

publication date

1 November 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24259600%20AND%20SRC:MED&resulttype=core&format=json

Annals of Pharmacotherapy

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24259600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

48

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24259600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

107-115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24259600%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24259600%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology and clinical management of XDR-TB: a systematic review by TBNET.

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Tuberculosis: cost of illness in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Shortening the treatment of tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

TMC207: the first compound of a new class of potent anti-tuberculosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

In search of new cures for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Microbiology. TB--a new target, a new drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

New drugs and regimens for treatment of TB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Infectious disease. Approval of novel TB drug celebrated--with restraint

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087

Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1060028013504087